Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy.
Each year, more than 30,000 Americans are diagnosed with pancreatic cancer. We have only made incremental advancements in treatment of pancreatic cancer despite our best efforts. Research has revealed that pancreatic cancer is a genetic disease which is associated with various forms of cancer associated genetic alterations. Identification and understanding of these carcinogenic gene alterations is the base upon which we can overcome drug resistance and develop novel treatment approaches. In this paper, we review current understanding of pharmacogenomics of pancreatic cancer treatment and address future direction of the field.
Kang
Soonmo Peter
SP
Saif
Muhammad Wasif
MW
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003603:Cytotoxins / Q000627:therapeutic use; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005544:Forecasting; D006801:Humans; D007206:Individuality; D009154:Mutation; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000628:therapy*; D010597:Pharmacogenetics; D017671:Platinum Compounds / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D003603:Cytotoxins; D017671:Platinum Compounds; D011743:Pyrimidines